You are here

Article Text

Article menu
Download PDFPDF
Commentary
Daclatasvir: a team player rather than a prima donna in the treatment of hepatitis C

https://doi.org/10.1136/gutjnl-2014-307958

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Contributors AA and RDF conceived and wrote the manuscript.

    • Competing interests AA: Advisory Board: AbbVie, Gilead Sciences. Speaker Bureau: AbbVie, Gilead Sciences, Janssen, Merck.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles

    • Hepatology
      Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study
      Christophe Hézode Gideon M Hirschfield Wayne Ghesquiere William Sievert Maribel Rodriguez-Torres Stephen D Shafran Paul J Thuluvath Harvey A Tatum Imam Waked Gamal Esmat Eric J Lawitz Vinod K Rustgi Stanislas Pol Nina Weis Paul J Pockros Marc Bourlière Lawrence Serfaty John M Vierling Michael W Fried Ola Weiland Maurizia R Brunetto Gregory T Everson Stefan Zeuzem Paul Y Kwo Mark Sulkowski Norbert Bräu Dennis Hernandez Fiona McPhee Megan Wind-Rotolo Zhaohui Liu Stephanie Noviello Eric A Hughes Philip D Yin Steven Schnittman
      Gut 2014; 64 948-956 Published Online First: 30 Jul 2014. doi: 10.1136/gutjnl-2014-307498